Analytical Data
-
基因名
ARHGEF7
- Application
-
别名
ARHGEF7；COOL1；KIAA0142；P85SPR；Rho guanine nucleotide exchange factor 7
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q14155
-
表达区间
179-428aa
-
氨基酸序列
MTDNSNNQLVVRAKFNFQQTNEDELSFSKGDVIHVTRVEEGGWWEGTLNGRTGWFPSNYVREVKASEKPVSPKSGTLKSPPKGFDTTAINKSYYNVVLQNILETENEYSKELQTVLSTYLRPLQTSEKLSSANISYLMGNLEEICSFQQMLVQSLEECTKLPEAQQRVGGCFLNLMPQMKTLYLTYCANHPSAVNVLTEHSEELGEFMETKGASSPGILVLTTGLSKPFMRLDKYPTLLKELERHMEDYH
-
分子量
55.3kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ARHGEF7, also known as an activating protein for Rho GTPases, is a member of the Rho guanine nucleotide exchange factor (GEF) family, playing a crucial role in the regulation of cellular signaling pathways that impact various physiological processes, including cell migration, proliferation, and morphology. Research has shown that ARHGEF7 is implicated in numerous diseases, particularly in cancer progression and metastasis, where its overexpression is often linked to invasive tumor characteristics. The interactions of ARHGEF7 with Rho GTPases such as RhoA, Rac1, and Cdc42 are pivotal in modulating the actin cytoskeleton and cell adhesion, making it a significant target for therapeutic intervention. In recent years, advances in recombinant protein technology have facilitated the production of ARHGEF7 for in vitro studies, allowing researchers to dissect its functional domains and regulatory mechanisms more effectively. The recombinant ARHGEF7 protein is utilized in biochemical assays to investigate its role in signal transduction and to identify potential small-molecule inhibitors or modulators that could influence its activity in pathological contexts. Overall, the study of ARHGEF7 as a recombinant protein not only enhances our understanding of Rho signaling but also holds promise for developing novel therapeutic strategies in cancer and other diseases associated with aberrant Rho GTPase activity.
